Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM-201 Extension in Pediatric GHD
NCT05796440Phase 2Enrolling by invitation
- Sponsor
- Lumos Pharma, Inc.
- Start
- Aug 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ibutamoren in idiopathic growth hormone deficiency (I-GHD), sponsored by Lumos Pharma, Inc.. Started Aug 2023; status: enrolling by invitation.
02
Drugs
ibutamoren
03
Conditions
idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on NCT05796440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796440.